Aktis Oncology, Inc.
AKTS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002035832
In the last 90 days, Aktis Oncology, Inc. insiders filed 0 open-market purchases and 5 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $1.10B in total; Soros Fund Management is the only superinvestor holding it.
Superinvestors holding AKTS, Q2 2026
1 superinvestor reports holding Aktis Oncology, Inc. on Form 13F, worth $3.22M in total. Weight is Aktis Oncology, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Soros Fund ManagementGeorge Soros | <0.1% | 100,000 | $3.22M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of AKTS each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
1 superinvestor holding at quarter end